Introduction
============

Schizophrenia is a mental disorder with an often chronic course, presenting with various symptoms including delusions, hallucinations, and impaired cognition. Multiple risk factors incorporating genetic susceptibility are associated with development of schizophrenia, indicating the underlying complexity of this debilitating condition. Epidemiological studies suggest that among many risk factors, obstetric complications, particularly those related to hypoxia during labor and delivery, are factors for increasing risk of schizophrenia ([@B22]; [@B33]; [@B68]; [@B18]). Moreover, another line of investigation suggests a strong genetic component to schizophrenia. This is exemplified by a recent Genome-Wide Association Study (GWAS) that identified a number of genetic elements that predispose to schizophrenia ([@B34]; [@B58]; [@B1]; [@B20]; [@B53]). On top of these separate viewpoints (i.e., environmental risk vs. genes), researchers highlight the likelihood of interplay between environmental risk and genes on predisposition to complex diseases such as schizophrenia ([@B38]).

The impact of perinatal asphyxia on postnatal life has been studied using a rodent model of global hypoxia during cesarean section birth, known as the asphyxia model. There are several types of asphyxia models according to the time of asphyxia exposure. One model which employed 15 (±1) min asphyxia in the perinatal period has demonstrated several behavioral, pharmacological, neurochemical, and neuroanatomical abnormalities in adulthood, which are relevant to schizophrenia. For instance, the model has shown increased spontaneous locomotor activity and hypersensitivity to injection of apomorphine, amphetamine, and cocaine ([@B8]; [@B65]; [@B32]). The same model has provided some evidence of impaired prepulse inhibition, implicated as a proxy measure for dysfunctional information processing underlying symptoms of schizophrenia ([@B30]; [@B42]). In addition, other studies that used the model have displayed a significant increase in catechol-*O*-methyltransferase (COMT) mRNA expression ([@B64]), and an increase in dopamine (DA) transporter density ([@B15]; [@B26]). In line with these findings, increased number of dopaminergic neurons has also been reported in the asphyxic rat brain ([@B8]). On the other hand, the other model which employed longer asphyxia (19--20 min) in the perinatal period has impairment in the GABAergic system in the striatum (Str) ([@B19]) and shown abnormal habituation memory in adulthood, which relevant to neurodevelopmental disorders ([@B57]). In this study, we placed importance on dopaminergic abnormalities in the 15 (±1) min asphyxia models. Because the abnormalities were in accordance with well-established findings in schizophrenia patients ([@B50]). Therefore, we used the 15 min asphyxia rat as an animal model of schizophrenia. It has also been reported that cesarean section itself is associated with schizophrenia ([@B16]), but so far this finding is inconsistent ([@B17]). In rats, cesarean section (hereafter "C-section") birth is sufficient to produce some abnormalities in the dopaminergic system, including increased spontaneous locomotor activity, hypersensitivity to amphetamine injection, and an increase in DA transporter density ([@B10]). Therefore, in this study, we also considered C-section as a potential exogenous insult.

As outlined above, previous asphyxia models have focused on the dopaminergic system. However, the process of asphyxia may also compromise other neural systems. Accordingly, we have previously found that expression of neuregulin 1 (*NRG1*), a schizophrenia risk gene ([@B23]), is significantly decreased in asphyxia-induced rats ([@B64]). The protein encoded by *NRG1* plays a role in regulation of synaptic plasticity and neurotransmission ([@B48]). Thus, these studies suggest that a process induced by asphyxia during the perinatal period may involve alterations in not only the dopaminergic but also wider neural regulatory systems, and further, that these alterations may be mediated by genes.

Recently, novel five schizophrenia loci were identified by the [@B58]. This study provided high quality genetic data using substantial sample sizes and an optimal experimental design ([@B58]). Therefore, we determined if these novel schizophrenia risk genes show altered expression in asphyxia-induced rats. Among these five novel schizophrenia risk genes, we focused on *Cnnm2, Csmd1*, and *Mmp16* in this study. Because, risk variants of *CNNM2, CSMD1*, and *MMP16* are suggested to be involved in one of symptoms of schizophrenia, cognitive impairment ([@B40]; [@B54]; [@B51]). We measured gene expression at three periods: neonatal (postnatal day 1, P1), adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). These time frames are generally used for animal models of schizophrenia and correspond to the timing of asphyxia and/or C-section event, onset, and the chronic stage of schizophrenia in humans ([@B6]; [@B4]; [@B29]). We analyzed expression levels of schizophrenia risk genes in rat brain tissue, specifically, the prefrontal cortex (Pfc), Str, and hippocampus (Hip), which are suggested to be critically involved in schizophrenia ([@B12]). Little is known about whether expressions of *Cnnm2, Csmd1*, and *Mmp16* are involved in maturation of the central nervous system (CNS). Hence, we also examined expressions of the novel schizophrenia risk genes during the course of differentiation and maturation of neural and glial cell lines to confirm involvement of the genes ([@B58]) in CNS maturation.

Materials and Methods {#s1}
=====================

Animals and Induction of Perinatal Asphyxia
-------------------------------------------

All animal experiments were performed in accordance with the Guide for Animal Experimentation at the Hamamatsu University School of Medicine. Intrauterine anoxia was induced in rats delivered by C-section according to a previously described method ([@B65], [@B64]). Pregnant female Sprague-Dawley rats (Japan SLC, Hamamatsu, Japan) within the last day of gestation were anesthetised by diethyl ether, and hysterectomised. The uterus, including fetuses, was placed in a water bath at 37°C to induce 15 min of asphyxia, which is associated with 100% survival. After delivery, the umbilical cord was ligated, and the pups left to recover on a heating pad for at least 40 min. Rats that had delivered normally were used as surrogate mothers. Each surrogate mother received four vaginally delivered pups from another surrogate mother, four C-section-delivered, and four asphyxia-exposed pups. One day after birth (P1), brain tissue was collected from anesthetised male rats. Other male rats were housed three per cage in a temperature- and humidity-controlled colony room, maintained on a 12-h light/dark cycle (07:00 to 19:00 h light on) and with food and water provided *ad libitum*, and brain tissue was collected under anesthesia at 5 and 12 weeks after birth. The animals were divided into three groups based on their delivery: vaginal delivery (V group: *n* = 7), C-section (C group: *n* = 6), or C-section with 15 min of perinatal asphyxia (A group: *n* = 8). The Pfc, Str, and Hip were dissected on ice and used for the quantitative real-time reverse-transcription-polymerase chain reaction (qRT-PCR) analysis. The brain regions were defined according to the atlas of Paxinos and Watson ([@B64]).

Cell Culture and Neuronal and Glial Differentiation
---------------------------------------------------

The SK-N-SH cell line was cultured in α-MEM (Nacalai Tesque, Kyoto, Japan) containing 10% (v/v) FBS (Life Technologies, Tokyo, Japan), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO~2~. The medium was changed every 2--3 days. The MO3.13 cell line was cultured in DMEM (Sigma--Aldrich) containing 10% (v/v) FBS (Life Technologies), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO~2~. Medium was changed every 2--3 days. To induce differentiations, SK-N-SH cells were treated with 10 μM ATRA ([@B45]; [@B63]) (Sigma--Aldrich) and MO3.13 cells were treated with 100 nM PMA ([@B47]) (Sigma--Aldrich). DMSO (0.1%; Sigma--Aldrich) was used as the negative control for both differentiation inductions.

RNA Isolation and Quantitative Real-Time Reverse-Transcription-Polymerase Chain Reaction (qRT-PCR)
--------------------------------------------------------------------------------------------------

Total RNA was isolated from brain tissue (including Pfc, Str, and Hip) and cell lines using TRIZOL Reagent (Invitrogen, Carlsbad, CA, United States). Total RNA was transcribed to cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen). qRT-PCR was performed using SYBR Green (Qiagen, Hilden, Germany). Relative quantification of the rat genes: ancient conserved domain-containing protein 2 (Cnnm2), CUB and Sushi multiple domains 1 (Csmd1), and matrix metallopeptidase 16 (Mmp16); and the human genes: neuron-specific enolase (NSE), myelin basic protein (MBP), CNNM2, CSMD1, and MMP16 were determined using the delta-delta C~T~ method ([@B13]). The constitutive gene, Gapdh/GAPDH, was used as the internal control. mRNA levels were expressed as fold change relative to the V group. The primer sequences for qRT-PCR were as follows: Cnnm2 sense, 5′-TTGTCAGCAGGACAGAGGTG-3′; antisense, 5′-GTCGCTCCGACTGAGAGAGT-3′; Csmd1 sense, 5′-ATCATTACCAGGGCACCAG-3′; antisense, 5′-TTTTCATGGCCAGCATAGC-3′; Mmp16 sense, 5′-AGCTTTCGTCCACAAGGAAA-3′; antisense, 5′-CCTTGAGGATGGATCTTGGA-3′; Gapdh sense, 5′-GACATGCCGCCTGGAGAAAC-3′; antisense, 5′-AGCCCAGGATGCCCTTTAGT-3′; NSE sense, 5′-AGGCCAGATCAAGACTGGTG-3′; antisense, 5′-CACAGCACACTGGGATTACG-3′; MBP sense, 5′-ATGGCTAGACGCTGAAAACC-3′; antisense, 5′-AGGGGCAAGTGGGATTAAAG-3′; CNNM2 sense, 5′-GAAGCCATCCTGGACTTCAA-3′; antisense, 5′-CTCCCCTTCAAACACTGGAA-3′; CSMD1 sense, 5′-CTGCCATTCTGGTTCCTTTC-3′; antisense, 5′-CTGTTTTCATGCCCAGCATA-3′; MMP16 sense, 5′-AATCTCCTCAGGGAGCATTTGTA-3′; antisense, 5′-TCCAGGTTCTACCTTGAGTATCTG-3′; GAPDH sense, 5′-ATCAGCAATGCCTCCTGCAC-3′; and antisense, 5′-TGGCATGGACTGTGGTCATG-3′.

Statistical Analysis
--------------------

Quantitative gene expression in brain tissue was analyzed using a two-way multivariate analysis of variance (two-way MANOVA) and analysis of variance (ANOVA). In this model, the three separate brain areas (Pfc, Str, and Hip) in each rat were not independent and mutually correlated, and were therefore together treated as dependent variables to allow for applying two-way MANOVA. ANOVA followed by Tukey's *post hoc* test was applied for analyzed gene expressions in individual group (V vs. A, C vs. A and V vs. A). For *in vitro* studies, two-tailed unpaired *t*-tests were used after no violation of the equal variance assumption was confirmed by *F*-test. All statistical analyses were set at a two-tailed α level of 0.05 for significance. The statistical analysis software, SPSS (version 12.0 J; SPSS, Inc., Chicago, IL, United States), was used for analyses.

Results
=======

Gene Expression in Three Brain Regions at Different Time Periods Following Hypoxic Insult at Birth
--------------------------------------------------------------------------------------------------

Expression levels of these genes in Pfc, Str, and Hip in the V group (*n* = 7), C group (*n* = 6), and A group (*n* = 8) at three time points (P1, 5W, and 12W) were measured by qRT-PCR (Supplementary Table [S1](#SM5){ref-type="supplementary-material"}). First, we determined if gene expression levels were altered in C-section rats compared with the V group. Two-way MANOVA with a grouping factor (V and C groups) and time point (P1, 5W, and 12W) as the fixed factors, and gene expression in three brain regions (Pfc, Str, and Hip) as the dependent variables, was performed separately for each gene. This analysis identified no significant grouping effect (*F*~3,31~ = 0.54, *P* = 0.65) for *Cnnm2* expression, suggesting there is no difference in gene expression between the C and V groups. Thus, these two groups of rats (V and C groups) were amalgamated to yield a single control group in subsequent analyses. However, gene expression in the remaining two genes, *Csmd1* and *Mmp16*, was found to differ according to the presence or absence of C-section. There was a significant grouping effect (*F*~3,31~ = 17.94, *P* \< 0.001 and *F*~3,31~ = 10.81, *P* \< 0.001, respectively) for *Csmd1* and *Mmp16*. These results indicate a moderate effect of C-section on expression of these two genes.

Following the MANOVA results comparing gene expression between the V and C groups, we next determined if *Cnnm2* gene expression differed between the A group and a combined control rat group (called the "VC group") (**Table [1](#T1){ref-type="table"}**). Two-way MANOVA revealed a significant grouping effect (*F*~3,55~ = 8.76, *P* \< 0.001), and an overall difference in *Cnnm2* expression between asphyxia-induced and control rats, with *Cnnm2* expression significantly lower in the A group compared with the VC group. Subsequent univariate analyses found group differences present in Pfc (*P* \< 0.001) and Str (*P* \< 0.001), but not Hip (*P* = 0.18). In addition, a significant time × group interaction was detected in Str (*P* = 0.019), but not Pfc (*P* = 0.100) by two-way ANOVA. This difference in quantified *Cnnm2* mRNA was apparent immediately after asphyxia (i.e., at P1) in striatal tissue, but became less marked afterward (at 5W and 12W) (**Figure [1B](#F1){ref-type="fig"}**). In contrast, as indicated by the non-significant time × group interaction in Pfc, decreased gene expression in asphyxia rats was persistent across all three time points, although the difference was minimized at 12W (**Figure [1A](#F1){ref-type="fig"}**). In supporting of this, when we analyzed *Cnnm2* expression in individual group (V vs. A, C vs. A, and V vs. A) by ANOVA, group differences in Pfc (V vs. A, *P* \< 0.001, Tukey's *post hoc* test; C vs. A, *P* = 0.008, Tukey's *post hoc* test) and Str (V vs. A, *P* = 0.018, Tukey's *post hoc* test; C vs. A, *P* = 0.004, Tukey's *post hoc* test) were also found (Supplementary Figures [S1A,B](#SM1){ref-type="supplementary-material"}).

###### 

Cnnm2 in three brain regions at different time periods following hypoxic insult at birth.

  Gene name   Brain region   VC group      A group                                                 
  ----------- -------------- ------------- ------------- ------------- ------------- ------------- -------------
  *Cnnm2*     Pfc            0.95 ± 0.06   1.05 ± 0.05   0.92 ± 0.07   0.61 ± 0.06   0.72 ± 0.04   0.86 ± 0.09
              Str            0.93 ± 0.05   1.00 ± 0.05   1.13 ± 0.05   0.54 ± 0.04   0.90 ± 0.06   1.07 ± 0.08
              Hip            0.88 ± 0.05   1.17 ± 0.08   0.92 ± 0.04   0.68 ± 0.05   1.09 ± 0.04   0.97 ± 0.09

Quantitative real-time reverse-transcription-polymerase chain reaction (qRT-PCR) quantification of

Cnnm2

expression in prefrontal cortex (Pfc), striatum (Str), and hippocampus (Hip) at neonatal (postnatal day 1, P1), adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). Values are expressed as mean ± SEM.

![*Cnnm2* expression of different brain regions at different time periods following hypoxic insult at birth. quantitative real-time reverse-transcription-polymerase chain reaction (qRT-PCR) quantification of *Cnnm2* expression in prefrontal cortex (Pfc) **(A)** and striatum (Str) **(B)** at neonatal (postnatal day 1, P1) adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). Relative *Cnnm2* expression was obtained by normalizing to *Gapdh* from the same cDNA. Results are calculated as a ratio of V group expression. Error bars represent mean ± SEM (VC group, *n* = 13; A group, *n* = 8).](fnmol-10-00341-g001){#F1}

Initial analyses revealed that *Csmd1* and *Mmp16* gene expression differed between the C and V groups, that is, due to the presence or absence of C-section. This finding of differing gene expression in association with C-section led us to speculate that C-section itself could be considered to be an exogenous insult, and may play a role in altering brain expression of these two genes. Further, we found no additional influence of asphyxia on expression levels of either gene, when the A group (asphyxia + C-section) and C group (C-section only) were compared (*F*~3,34~ = 0.49, *P* = 0.69 and *F*~3,34~ = 0.678, *P* = 0.57; for *Csmd1* and *Mmp16* expression, respectively). Because there was no difference in gene expression between rats that had received a C-section, we combined the two rat groups (A and C groups) to yield one C-section group (CS group). Next, we compared gene expression levels between the V and CS groups (**Table [2](#T2){ref-type="table"}**).

###### 

Csmd1 and Mmp16 expression in three brain regions at different time periods following C-section at birth.

  Gene name   Brain region   V group       CS group                                                
  ----------- -------------- ------------- ------------- ------------- ------------- ------------- -------------
  *Csmd1*     Pfc            1.00 ± 0.08   1.00 ± 0.09   1.00 ± 0.15   2.46 ± 0.58   1.07 ± 0.04   0.86 ± 0.09
              Str            1.00 ± 0.03   1.00 ± 0.12   1.00 ± 0.08   1.55 ± 0.11   1.14 ± 0.08   1.34 ± 0.07
              Hip            1.00 ± 0.06   1.00 ± 0.05   1.00 ± 0.05   1.94 ± 0.24   1.19 ± 0.09   0.92 ± 0.08
  *Mmp16*     Pfc            1.00 ± 0.06   1.00 ± 0.08   1.00 ± 0.17   2.70 ± 0.72   1.15 ± 0.11   0.95 ± 0.09
              Str            1.00 ± 0.07   1.00 ± 0.10   1.00 ± 0.04   1.69 ± 0.19   0.97 ± 0.06   1.16 ± 0.06
              Hip            1.00 ± 0.06   1.00 ± 0.05   1.00 ± 0.04   1.55 ± 0.27   1.13 ± 0.08   1.43 ± 0.45

Quantitative real-time reverse-transcription-polymerase chain reaction quantification of

Cnnm2

expression in prefrontal cortex (Pfc), striatum (Str), and hippocampus (Hip) at neonatal (postnatal day 1, P1), adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). Values are expressed as mean ± SEM.

As for *Csmd1*, two-way MANOVA revealed a significant grouping effect (*F*~3,55~ = 12.104, *P* \< 0.001). Univariate analyses found group differences in Str (*P* \< 0.001) and Hip (*P* = 0.011), but not Pfc (*P* = 0.085). Subsequent ANOVA showed a significant time × group interaction in Hip (*P* = 0.007), but not Str (*P* = 0.128). As implicated by the non-significant time × group interaction, increased *Csmd1* expression in the CS group in Str was relatively constant across all three time points, although the difference was somewhat minimized at 5W (**Figure [2A](#F2){ref-type="fig"}**). In Hip, elevated *Csmd1* expression was present at P1 (i.e., immediately after C-section), but became less marked afterward (i.e., at 5W and 1W) (**Figure [2B](#F2){ref-type="fig"}**). We also found group differences of *Csmd1* expression in individual group in Str (V vs. A, *P* = 0.002, Tukey's *post hoc* test; V vs. C, *P* = 0.002, Tukey's *post hoc* test) and Hip (V vs. C, *P* = 0.017, Tukey's *post hoc* test) by ANOVA (Supplementary Figures [S2A,B](#SM2){ref-type="supplementary-material"}). There is no group difference between V and A in Hip. It may due to low statistical power because of small sample size.

![Csmd1 expression of different brain regions at different time periods following C-section at birth. qRT-PCR quantification of Csmd1 expression in Str **(A)** and hippocampus (Hip) **(B)** at neonatal (postnatal day 1, P1) adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). Relative Csmd1 expression was obtained by normalizing to Gapdh from the same cDNA. Results are expressed as a ratio of V group expression, resulting in a V group ratio of 1. Error bars represent mean ± SEM (V group, *n* = 7; CS group, *n* = 14).](fnmol-10-00341-g002){#F2}

With regard to *Mmp16*, two-way MANOVA revealed a significant grouping effect (*F*~3,55~ = 4.60, *P* = 0.006). Subsequent univariate analyses indicated that the group difference was present in Str only (*P* = 0.009), while two-way ANOVA detected a significant time × group interaction in Str (*P* = 0.016). *Mmp16* expression in Str began at a higher level in the CS group than the V group at P1, but the difference became less marked afterward (**Figure [3](#F3){ref-type="fig"}**). We also found group difference of *Mmp16* expression in individual group in Str (V vs. C, *P* = 0.012, Tukey's *post hoc* test) by ANOVA (Supplementary Figure [S3](#SM3){ref-type="supplementary-material"}). There is no group difference between V and A, may due to low statistical power because of small sample size.

![Mmp16 expression of different brain regions at different time periods following C-section at birth. qRT-PCR quantification of Mmp16 expression in Str at neonatal (postnatal day 1, P1) adolescence (5-week-old, 5W), and adulthood (12-week-old, 12W). Relative Mmp16 expression was obtained by normalizing to Gapdh from the same cDNA. Results are expressed as a ratio of V group expression, resulting in a V group ratio of 1. Error bars represent mean ± SEM (V group, *n* = 7; CS group, *n* = 14).](fnmol-10-00341-g003){#F3}

Altered Expression of Novel Schizophrenia Risk Genes during Differentiation of Neuronal and Glial Cell Lines
------------------------------------------------------------------------------------------------------------

To investigate involvement of these genes in CNS development, we measured mRNA expression during neuronal differentiation and glial maturation in human cell lines. The human neuroblastoma cell line, SK-N-SH, was treated with ATRA (10 μM) to induce neuronal differentiation. After 72 h treatment, gene expression of the neuronal differentiation maker, NSE, was clearly increased (*P* \< 0.001, two-tailed unpaired *t*-test) (Supplementary Figure [S4A](#SM4){ref-type="supplementary-material"}). Additionally, the human oligodendrocytic cell line, MO3.13, was treated with PMA (100 nM) to induce oligodendrocytic maturation. After 96 h treatment, gene expression of the oligodendrocytic differentiation maker, MBP, was substantively increased (*P* \< 0.001, two-tailed unpaired *t*-test) (Supplementary Figure [S4B](#SM4){ref-type="supplementary-material"}).

We then measured *CNNM2, CSMD1*, and *MMP16* expression during the differentiation processes. During neuronal differentiation, *CNNM2* and *MMP16* expression were significantly increased (*P* \< 0.001 and *P* = 0.031, respectively) (**Figure [4A](#F4){ref-type="fig"}**). *CSMD1* was undetectable in both undifferentiated and differentiated SK-N-SH cells. During oligodendrocytic maturation, *CNNM2* and *MMP16* expression were significantly decreased (both *P* \< 0.001), while *CSMD1* expression was significantly increased in MO3.13 cells (*P* \< 0.001) (**Figure [4B](#F4){ref-type="fig"}**).

![Alteration of expression of novel schizophrenia risk genes during differentiation of neuronal and glial cell lines. qRT-PCR quantification of CNNM2, CSMD1, and MMP16 expression during neuronal differentiation of SK-N-SH cells **(A)** and oligodendrocytic maturation of MO3.13 cells **(B)**. Relative CNNM2, CSMD1, and MMP16 expression were obtained by normalizing to GAPDH from the same cDNA. Results are expressed as a ratio of control (undifferentiated cells) expression, resulting in a control ratio of 1. Error bars represent mean ± SD (*n* = 3--4 per treatment). ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 between control cells and cells treated with ATRA (for SK-N-SH cells) or PMA (for MO3.13 cells).](fnmol-10-00341-g004){#F4}

Discussion
==========

Here, we investigated the schizophrenia risk genes, *CNNM2, CSMD1*, and *MMP16* ([@B58]), and identified alterations in gene expression in the asphyxia rat model for schizophrenia. In addition, we examined the influence of C-section on gene expression. Interestingly, we found that among the three genes examined, *Cnnm2* was related specifically to the asphyxia process, whereas the other two (*Csmd1* and *Mmp16*) were associated with C-section. *Cnnm2* expression was significantly downregulated in Pfc and Str under the influence of asphyxia. While such downregulation was observed only at the neonatal period in Str, it was sustained into adolescence in Pfc. In contrast, exposure to C-section was related to upregulated *Csmd1* and *Mmp16* expression. Moreover, altered *Csmd1* expression levels were conserved until adulthood in Str, but were transient in Hip. Furthermore, *Mmp16* expression was strikingly upregulated, but only immediately after C-section in Str. Using human cell lines, we provided some evidence indicative of potential involvement of *CNNM2, CSMD1*, and *MMP16* in CNS development.

Effect of Asphyxia on *CNNM2* Expression
----------------------------------------

*CNNM2* is a member of the ancient conserved domain-containing protein family ([@B66]). Members of this protein family contain a sequence motif that is present in the cyclin box, specifically, a cyclic nucleotide-monophosphate (cNMP)-binding domain ([@B66]). The *CNNM2* gene has a ubiquitous expression pattern in humans ([@B66]), and is highly expressed in the brain^[1](#fn01){ref-type="fn"}^. However, little is known about expression levels of *CNNM2* in the brain of schizophrenia patients compared with control subjects.

To our knowledge, this is the first study to show that *Cnnm2* expression is downregulated in Pfc and Str in the asphyxia model. Notably, the reduction was maintained until adulthood in Pfc, but was restricted to the perinatal period in Str. It has been reported that schizophrenia patients with obstetric complications show worsened Pfc dysfunction, such as higher intensity of negative symptoms and worse performance on Wisconsin Card Sorting Test (WCST) measures, compared to those without complications ([@B14]). This suggests that the event of asphyxia may affect CNS-related gene expression, and altered gene expression continues to play a role in disturbing brain function, resulting in formation of schizophrenia symptoms.

In our human cell line experiments, we found increased *CNNM2* expression during neuronal differentiation. Additionally, because our *in vitro* experiments show that mature neurons express *CNNM2* more than undifferentiated cells, and further, that *CNNM2* expression is reduced in asphyxia-induced rats, it is possible that mature neurons may be decreased, especially in the prefrontal region in the asphyxia model. Intriguingly, in line with our findings, it has been reported that a *CNNM2* variant ([@B58]) is associated with gray matter morphological vulnerability of the bilateral inferior frontal gyri ([@B52]).

A number of brain imaging studies have demonstrated decreased myelin integrity in schizophrenia ([@B46]). However, the maturation status of oligodendrocytes in the brain of schizophrenia patients is unknown. Of note in this context, is a study showing abnormal cell cycle re-entry in postmitotic oligodendrocytes in the brains of schizophrenia patients, with mitotically active oligodendrocytes functionally deficient in schizophrenia ([@B39]). Intriguingly, it has been suggested that cell division increases the number of mitotically active oligodendrocytes ([@B39]). In addition, mRNA levels of myelin-associated oligodendrocyte basic protein (MOBP), an oligodendrocyte-associated gene, are increased in Pfc white matter in schizophrenia patients ([@B49]). We found that reduced *Cnnm2* expression levels correlated with enhanced oligodendrocytic maturation in the human SK-N-SH cell line. Thus, our finding of reduced *Cnnm2* expression in the asphyxia model suggests that an accelerated maturational process may take place in oligodendrocytes from an early developmental stage, due to asphyxia exposure during the perinatal period, resulting in abnormal regulation of the oligodendrocyte cell cycle and an unusual maturation pattern. This scenario may be relevant to disturbed myelin integrity in schizophrenia.

CNNM2 has been proposed as a Mg^2+^ transporter in Xenopus oocytes ([@B35]), whereas human CNNM2 is a principal molecular factor of intracellular Mg^2+^ homeostasis but not a Mg^2+^ transporters *per se* ([@B60]). Intriguingly, knockdown of *CNNM2* orthologs in zebrafish resulted in impaired brain development and reduced body Mg content ([@B3]). Further study is needed to understand the underlying molecular mechanisms of CNNM2 in the brain development and the pathophysiology of schizophrenia.

Here, we failed to find any change in *Cnnm2* expression in Hip in the asphyxia model, despite numerous studies reporting various functional and structural hippocampal changes in the asphyxia model ([@B9]). There is the possibility that hippocampal abnormalities in relation to asphyxia may be accounted for by genes other than the genes examined in this study.

Effect of C-Section on CSMD1 and MMP16 Expression
-------------------------------------------------

Despite evidence showing that undergoing C-section at birth is itself associated with later development of schizophrenia ([@B16]), there is inconsistency in the literature ([@B17]). C-section delivery is also associated with other types of neurodevelopmental disorders, such as autism spectrum disorders and attention deficit hyperactivity disorder ([@B21]). We found that C-section was related to increased *Csmd1* and *Mmp16* expression.

*CSMD1* encodes the CUB and Sushi multiple domains 1 protein. CSMD1 protein is highly expressed in regions of neuronal differentiation and outgrowth, and remains high in the adult in areas of increased neuronal plasticity, such as the cerebral cortex and Hip ([@B41]). It has been suggested that CSMD1 is an important regulator of complement activation and inflammation in the developing CNS, and also that it plays a role in growth cone function ([@B41]). Recently, a *CSMD1* variant ([@B58]) was associated with comparatively reduced cortical activation in the middle occipital gyrus and cuneus, a posterior brain region that supports maintenance processes during performance of a spatial working memory task, and affects general cognitive ability and executive function in healthy persons ([@B40]). In addition to this variant ([@B58]), other variants of this gene have been associated with increased risk for schizophrenia ([@B37]; [@B56]) and associated with illness severity at end point ([@B56]).

This study is the first to show increased *Csmd1* expression in Str and Hip in relation to C-section. Of particular interest is the long-lasting change in striatal expression throughout adulthood. This is in accordance with the findings of long-term changes in dopaminergic parameters, such as tyrosine hydroxylase activity and DA transporter density in Str caused by C-section in the rat ([@B27]; [@B11]). Further, it has been reported that genetic variation of *CSMD1* ([@B58]) plays a role in the ratio between DA and serotonin metabolites in CSF ([@B44]). These studies suggest that the event of C-section may intervene in gene expression, particularly *CSMD1* expression in Str, and altered gene expression continues to play a role in disturbing function of the monoaminergic systems (in particular the dopaminergic system), resulting in psychotic symptoms. In human SK-N-SH cells, we found that *CSMD1* was involved in oligodendrocytic maturation. Along with this, the fact that *Csmd1* expression is upregulated in the C-section model suggests that C-section may exert a facilitatory effect on oligodendrocyte maturation. Further, a metabolic connection has been demonstrated between myelinating oligodendrocytes and axons ([@B31]), and metabolite levels in fronto-striatal-thalamic white matter pathways differ in patients with schizophrenia compared with control subjects ([@B5]). As mentioned above, it has been suggested that abnormal regulation of the oligodendrocyte cell cycle and an unusual maturation pattern may underlie schizophrenia ([@B39]; [@B49]). It is possible that myelin integrity may be disturbed by unusual oligodendrocyte developmental processes in schizophrenia. These processes may be mediated by long-lasting changes in risk gene expression.

*MMP16* encodes for a matrix metalloproteinase family protein, which is involved in extracellular matrix breakdown in normal physiological processes such as embryonic development, reproduction, and tissue remodeling, as well as in physical disease processes ([@B2]). Mmp16 mRNA is strongly expressed in the rat brain ([@B59]), and equally expressed in gray and white matter, suggesting possible roles for MMP16 in CNS development and/or function ([@B67]).

We found that C-section led to upregulated *Mmmp16* expression in Str, which was observed immediately after C-section. We also found that gene expression increased during neuronal differentiation and decreased during oligodendrocytic maturation in human cell lines. Gray and white matter abnormalities are present in schizophrenia at illness onset ([@B24]). Therefore, it is possible that changes in *MMP16* expression early in life may compromise gray and white matter construction by accelerating neural differentiation and affecting oligodendrocyte maturation.

Molecular mechanisms which mediate the influence of CSMD1 and MMP16 on brain development and the pathobiology of schizophrenia remain unresolved. Further research is needed exploring these mechanisms.

In this study, we considered both asphyxia and C-section to equally play a role in predisposition to schizophrenia phenotypes. However, aetiological engagement of C-section might be weaker than asphyxia, because epidemiological studies of the former are inconsistent ([@B16]; [@B17]). Rat pups born by C-section show normal or slightly reduced oxygen partial pressure levels at birth and signs of mild respiratory distress during the 1st day of life ([@B25]; [@B61]; [@B7]). Thus, mild hypoxia (but not the level required for asphyxia) may be induced by C-section. Of note, human neonates born by C-section also suffer from increased occurrence of mild respiratory distress during the 1st days of life ([@B36]; [@B62]). However, since circumstances surrounding C-section in clinical practice may be complex, animal models may not wholly represent all aspects of C-section as occurs in humans. Indeed, [@B17] reported significant differences between schizophrenic and comparison subjects for emergency C-sections but not for elective C-sections.

Our model of asphyxia and C-section rats showed more salient changes in those gene expressions in Str relative to Pfc and Hip. These findings are in line with the view that Str is one of the most sensitive areas to asphyxia ([@B43]; [@B28]).

Limitation
----------

In this study, we examined multiple genes in three brain regions at three time points. There is a potential error in interpretation due to the nature of multiple testing. To attenuate this risk, we analyzed intergroup differences in three brain regions, instead of each brain region separately, by applying MANOVA. Based on the results, we proceeded to univariate analyses. Following Rothman's suggestion ([@B55]), we did not thoroughly adjust for multiple comparisons in the analysis, which may have led to eliminating any heuristic indication of results from this study. Nevertheless, there is a potential risk of false-positives, and further study is clearly warranted.
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